Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

Hyperthermia in Conjunction with Cancer Chemotherapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Title: Hyperthermia in Conjunction with Cancer Chemotherapy.

Agency: Agency for Health Care Policy and Research/Center for Health Care Technology (Formerly, the Office of Health Technology Assessment).

Contact: Ira Green, M.D., Medical Officer; Thomas V. Holohan, M.D., Director, CHCT.

Status: Technology Assessment: Published, 1991.

Language: English.

Primary Objective: To determine whether hyperthermia alone or in conjunction with chemotherapy resulted in an increase in response or survival rates in patients with cancer.

Methods Used: Review of the literature, consultation with U.S. Public Health Service, NIH and FDA. Information was also obtained from individuals and organizations with an interest in hyperthermia.

Data Identification: MEDLINE® search of articles published between 1967-1990.

Study Selection: Seventy-six references were selected that addressed the usefulness of these therapies; book chapters were also consulted.

Data Extraction: Papers were analyzed as to whether they were prospective randomized trials or case series, the types and uniformity of the patients studied, the duration of followup, the criteria and types of response and the hyperthermia and chemotherapeutic methods used.

Key Findings: There is no objective and reliable evidence that hyperthermia alone or in conjunction with chemotherapy produces increased response rates or longer survival times in patients with cancer. The only exception is the use of hyperthermic regional perfusion with melphalan for the treatment of a limb melanoma.

Conclusion: Hyperthermia alone or combined with chemotherapy is not, with one exception, a useful treatment for cancer.

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care